[an error occurred while processing this directive] ����Ƥ���Բ�ѧ��־ 2003, 29(6) 358-360 DOI:     ISSN: 2096-5540 CN: 32-1880/R

����Ŀ¼ | ����Ŀ¼ | ������� | �߼�����                                                            [��ӡ��ҳ]   [�ر�]
����
��չ����
������Ϣ
Supporting info
PDFȫ��
[HTMLȫ��]
�����
�����뷴��
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
����
Email Alert
���·���
���������Ϣ
���Ĺؼ����������
���ʽ�������ø
��������ø����֯���Ƽ�
�����֯����
���������������
���ĺ�
֣��
PubMed
Article by
Article by

���ʽ�������ø������֯��

���ĺ�, ֣��

�㽭��ѧҽѧԺ�����ڶ�ҽԺƤ����, ���� 310009

ժҪ��

���ʽ�������ø��һ���������������ϸ������ʽ���ø,�����ڿ��ɶ��ֻ���ϸ������֢ϸ������,�����巢������֯�ؽ����޸�����֢��Ӧ��������Ϯ��ת�Ƶȹ����з�����Ҫ����.���Ի��ʽ�������ø�����������Խ����֯���Ĺ�ϵ��һ����.

�ؼ����� ���ʽ�������ø   ��������ø����֯���Ƽ�   �����֯����  

Abstract:

Keywords:
�ո����� 2003-01-10 �޻�����  ����淢������  
DOI:
������Ŀ:

ͨѶ����:
���߼��:

�ο����ף�
[1] Sternlicht MD,Werb Z.How matrix metalloproteinases regulate cell behavior.Annu Rev Cell Dev Biol,2001,17:463-516.
[2] Corbel M,Belleguic C,Boichot E,et al.Involvement of gelatinases(MMP-2 and MMP-9)in the development of airway inflammationand pulmonary fibrosis.Cell Biol Toxicol,2002,18(1):51-61.
[3] Leeman MF,Curran S,Murray GI.The structure,regulation,and function of human matrix metalloproteinase-13.Crit Rev BiochemMol Biol,2002,37(3):149-166.
[4] Khasigov PZ,Podobed OV,Ktzoeva SA,et al.Matrix metalloproteiases of normal human tissues.Biochemistry(Mosc),2001,66(2):130-140.
[5] Rydziel S,Durant D,Canalis E.Platelet-derived growth factor induces collagenase 3 transcription in osteoblasts through the activator protein 1 complex.J Cell Physiol,2000,184(3):326-333.
[6] Lijnen HR.Matrix metalloproteinases and cellular fibrinolytic activity.Biochemistry(Mosc),2002,67(1):92-98.
[7] Brew K,Dinakarpandian D,Nagase H.Tissue inhibitors of metalloproteinases:evolution,structure and function.Biochim Biophys Acta,2000,1477(1-2):267-283.
[8] Lohi J,Wilson CL,Roby JD,et al.Epilysin,a novel human matrix metalloproteinase(MMP-28)expressed in testis and keratinocytes and in response to injury.J B iol C hem,2001,276(13):10134.
[9] Kotajima L,Aotsuka S,Fujimani M,et al.Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis.Clin Exp Rheumatol,1998,16(4):409-415.
[10] Zucker S,Mian N,Drews M,et al.Increased serum stromelysin-1 levels in systemic lupus erythematosus:lack of correlation with disease activity.J Rheumatol,1999,26(1):78-80.
[11] Zucker S,Hymowitz M,Conner C,et al.Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues.Clinical and experimental applications.Ann N Y Acad Sci,1999,878:212-227.
[12] Ribbens C,Martin y Porras M,Franchimont N,et al.Increased matrix metalloproteinase-3 serum levels in rheumatic diseases:relationship with synovitis and steroid treatment.Ann Rheum Dis,2002,61(2):161-166.
[13] Faber-Elmann A,Sthoeger Z,Tcherniack A,et al.Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus.Clin Exp Immunol,2002,127(2):393-398.
[14] Kieseier BC,Schneider C,Clements JM,et al.Expression of specific matrix metalloproteinases in inflammatory myopathies.Brain,2001,124(Pt 2):341-351.
[15] Choi YC,Dalakas MC.Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies.Neurology,2000,54(1):65-71.
[16] Young-Min SA,Beeton C,Laughton R,et al.Serum TIMP-1,TIMP-2,and MMP-1 in patients with systemic sclerosis,primary Raynaud's phenomenon,and in normal controls.Ann Rheum Dis,2001,60(9):846-851.
[17] Yazawa N,Kikuchi K,Ihn H,et al.Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.J Am Acad Dermatol,2000,42(1Pt 1):70-75.
[18] Kikuchi K,Kubo M,Hoashi T,et al.Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis.Clin Exp Dermatol,2002,27(4):301-305.
[19] Perez P,Goicovich E,Alliende C,et al.Differential expression of matrix metalloproteinases in labial salivary glands of patients with primary Sjogren's syndrome.Arthritis Rheum,2000,43(12):2807.
[20] Tolboom TC,Pieterman E,van der Laan WH,et al.Invasive properties of fibroblast-like synoviocytes:correlation with growth characteristics and expression of MMP-1,MMP-3,and MMP-10.Ann Rheum Dis,2002,61(11):975-980.
[21] Petrow PK,Wernicke D,Schulze Westhoff C,et al.Characterisation of the cell type-specificity of collagenase 3 mRNA expression in comparison with membrane type 1 matrix metalloproteinase and gelatinase A in the synovial membrane in rheumatoid arthritis.Ann Rheum Dis,2002,61(5):391-397.
[22] Cunnane G,Fitzgerald O,Beeton C,et al.Early joint erosions and serum levels of matrix metalloproteinase 1,matrix metalloproteinase 3,and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.Arthritis Rheum,2001,44(10):2263-2274.
[23] Close DR.Matrix metalloproteinase inhibitors in rheumatic diseases.Ann Rheum Dis,2001,60(Suppl 3):iii62-67.
�������������
1������ǿ,�̲�.�����ش�ë�����������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2007,33(4): 244-
2����ȼ �±�.�����Ե�����֯���Լ������[J]. ����Ƥ���Բ�ѧ��־, 2011,37(6): 380-383
3�������� ������.���ʽ�������ø����ʽ�������ø���Ƽ��ڹ��ϻ������õ��о���չ[J]. ����Ƥ���Բ�ѧ��־, 2012,38(3): 163-166
4������ �浤.���ʽ�������ø��Ƥ���������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(1): 53-53
5���Ժ�� ���.���ʽ�������ø������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 148-148
6���º������, ��������У.Ƥ���еĻ��ʽ�������ø[J]. ����Ƥ���Բ�ѧ��־, 1999,25(2): 104-106
7���ļ�ƽ, ��־��.Ƥ�����ϻ������о���չ[J]. ����Ƥ���Բ�ѧ��־, 2002,28(5): 288-291
8������, ������.Ƥ����״ϸ�����ͻ���ϸ�������ʽ�������ø��P��������ת�ƵĹ�ϵ[J]. ����Ƥ���Բ�ѧ��־, 2004,30(3): 176-178
9������, �浤.���ʽ�������ø��Ƥ���������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(1): 53-55
10���Ժ��, ���.���ʽ�������ø������Ƥ������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 148-150
11���º�, �ィ��.���ʽ�������ø�����Ƥ��������[J]. ����Ƥ���Բ�ѧ��־, 2007,33(3): 151-153

�������� (��ע��:��վʵ�������Ը�, �벻Ҫ������ѧ���޹ص�����!�������ݲ�����վ�۵�.)

Copyright 2008 by ����Ƥ���Բ�ѧ��־